Shanghai, March 24, 2022: Regor Therapeutics Group and NVIDIA Corporation today entered into collaboration that makes Regor Therapeutics Group a unique biotech company in China to have in-depth access to NVIDIA Inception. Regor Therapeutics Group will work closely with NVIDIA to integrate high performance computing technology into Regor's proprietary Artificial Intelligence innovation platform - rCARD^TM - to accelerate the discovery and development of innovative drugs.

The NVIDIA Inception is a program designed to nurture pioneering biotech startups. In this collaboration, NVIDIA will contribute its industry-leading GPU products and high performance computing to the rCARD^TM platform, including NVIDIA Clara Discovery and the AutoDock-GPU suite. By leveraging GPU-powered parallel processing capabilities across multiple computing nodes, the rCARD^TM platform will aim to accelerate the drug discovery process, reduce R&D costs, and improve success rate of drug development. This collaboration marks another milestone in Regor's mission to accelerate innovation and bring breakthrough innovative drugs to patients worldwide.

The rCARD^TM platform is a proprietary and highly efficient drug discovery and development platform. With foundations of scientific expertise in structural biology, computational biology and computational chemistry, the rCARD^TM platform fully integrates advanced artificial intelligence algorithms with the extensive knowledge and experiences of our seasoned drug hunters in drug research and discovery. Regor is aiming to expand the capabilities of the rCARD^TM platform and build a new generation of world-class innovative drug discovery engine through this collaboration.

"We are very excited about AI in drug discovery and its potential disruptive impacts in our industry," said Dr. Wenge Zhong, Chief Technology Officer of Regor Therapeutics Group, "Since the inception, Regor has built an interdisciplinary team of scientists and embarked on establishing the rCARD^TM platform to integrate artificial intelligence with our collective knowledge and experience in drug discovery. We are pleased to enter into this holistic collaboration with industry leader NVIDIA in AI and high performance computing to further expand and strengthen our rCARD^TM platform capabilities. We hope that together NVIDIA and Regor can help to demonstrate the power of AI in the discovery and development of innovative drugs that will benefit patients around the world."

Renee Yao, director of global healthcare startups at NVIDIA, said: "We are excited to partner with Regor Therapeutics Group to unveil a new chapter in the integration of artificial intelligence into the biopharmaceutical industry. Through this partnership, we will enable Regor to systematically enhance its HPC and AI capabilities on top of NVIDIA's software-defined computing platform, accelerating the convergence of multidisciplinary technologies such as big data, artificial intelligence, high performance computing and innovative drug development. "

About Regor Therapeutics Group

Regor Therapeutics Group is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARD^TM (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARD^TM with structural biology, computational biology, computational chemistry and other disciplines, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules. To learn more about Regor, please visit us at www.regor.com.

IR Contact:

  Investor Relations and Communications

  Email: ir@regor.com

Shanghai, March 19, 2022: Today, Qilu Regor Therapeutics Inc. ("Regor") and two of its co-founders, Dr. Xiayang Qiu and Dr. Min Zhong, filed their responses in the Connecticut federal district court to a lawsuit filed by Pfizer Inc. ("Pfizer") in early February. In their court filing, Regor, Dr. Qiu, and Dr. Zhong not only rejected each of Pfizer's baseless allegations, but further raised multiple counterclaims, asking that the court issue a declaratory judgment that they never misappropriated any Pfizer trade secrets and that Regor is the rightful owner of the underlying patents.

The court filing explains in detail how Regor has independently discovered its drug candidates. Specifically, Regor's Chief Technology Officer, Dr. Wenge Zhong, who was the Senior Director and Head of Discovery Modalities at Amgen's Asia Research and Development Center before joining Regor, led a team of dedicated scientists and collaborated with a network of world-leading contract research organizations ("CROs") in China in expediting the discovery and development of the novel and inventive molecules in Regor's patent applications. The court filing demonstrates that, contrary to Pfizer's claims, Regor's patents were not built on trade secret misappropriation, but on the basis of literature and patents in the public domain and Regor team's ingenuity and hard work. Moreover, armed with Regor's proprietary Computer Accelerated Rational Discovery ("CARD") platform, which is now used consistently to facilitate target prioritization, decision making, and acceleration of the entire discovery process, Regor has made impressive achievements well beyond the GLP-1 related patents mentioned in this lawsuit: Regor has filed over 30 patents for ten drug discovery programs across three therapeutic areas in less than 4 years.

The court filing also explains Dr. Xiayang Qiu and Dr. Min Zhong's true reason for departing from Pfizer and co-founding Regor and further refutes Pfizer's meritless allegation of trade secret misappropriation. The court filing further points out that, while Pfizer had access to much of the information on which its lawsuit is based when Dr. Min Zhong and Dr. Xiayang Qiu left Pfizer in mid-2018, Pfizer did not express any concerns over their departures until over three and half years later, after Regor began to show promising signs of success.

"We never misappropriated Pfizer's trade secrets and we are confident that, once the truth comes to light, we will prevail in this litigation." said Dr. Min Zhong, co-founder and COO of Regor.

"We will vigorously defend against this meritless lawsuit," Xiayang Qiu, Regor's co-founder and CEO, commented, "but Regor will not be distracted by this lawsuit and remains committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally."

About Regor Therapeutics Group

Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating CARD with structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules. For more information, please click www.regor.com

###

IR Contact:

  Investor Relations and Communications

  Email: ir@regor.com